1. Home
  2. EMA vs UTHR Comparison

EMA vs UTHR Comparison

Compare EMA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMA
  • UTHR
  • Stock Information
  • Founded
  • EMA 1998
  • UTHR 1996
  • Country
  • EMA Canada
  • UTHR United States
  • Employees
  • EMA N/A
  • UTHR N/A
  • Industry
  • EMA Electric Utilities: Central
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMA Utilities
  • UTHR Health Care
  • Exchange
  • EMA Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • EMA 14.3B
  • UTHR 20.7B
  • IPO Year
  • EMA N/A
  • UTHR 1999
  • Fundamental
  • Price
  • EMA $47.83
  • UTHR $455.77
  • Analyst Decision
  • EMA
  • UTHR Buy
  • Analyst Count
  • EMA 0
  • UTHR 16
  • Target Price
  • EMA N/A
  • UTHR $472.94
  • AVG Volume (30 Days)
  • EMA 132.8K
  • UTHR 624.9K
  • Earning Date
  • EMA 01-01-0001
  • UTHR 10-29-2025
  • Dividend Yield
  • EMA 4.37%
  • UTHR N/A
  • EPS Growth
  • EMA 15.04
  • UTHR 16.08
  • EPS
  • EMA 2.18
  • UTHR 26.38
  • Revenue
  • EMA $6,033,610,485.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • EMA $22.07
  • UTHR $13.82
  • Revenue Next Year
  • EMA N/A
  • UTHR $5.71
  • P/E Ratio
  • EMA $21.84
  • UTHR $16.96
  • Revenue Growth
  • EMA 12.01
  • UTHR 13.50
  • 52 Week Low
  • EMA $43.90
  • UTHR $266.98
  • 52 Week High
  • EMA $49.77
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • EMA 45.78
  • UTHR 62.88
  • Support Level
  • EMA $46.94
  • UTHR $430.02
  • Resistance Level
  • EMA $49.77
  • UTHR $479.50
  • Average True Range (ATR)
  • EMA 0.52
  • UTHR 14.66
  • MACD
  • EMA -0.23
  • UTHR 0.41
  • Stochastic Oscillator
  • EMA 31.45
  • UTHR 65.30

About EMA Emera Incorporated Common Shares

Emera is a geographically diverse energy and services company investing in electricity generation, transmission, and distribution as well as gas transmission and utility energy services. Emera has operations throughout North America and the Caribbean countries.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: